A FIRST-TIME-IN-HUMAN STUDY TO ASSESS THE SAFETY, TOLERABILITY, PHARMACOKINETICS, AND PHARMACODYNAMICS OF ASCENDING DOSES OF GSK189075A IN HEALTHY SUBJECTS AND IN SUBJECTS WITH TYPE 2 DIABETES MELLITUS: